Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cara Therapeutic

CARA
Current price
0.66 USD -0.024 USD (-3.50%)
Last closed 0.69 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 41 762 956 USD
Yield for 12 month -83.76 %
1Y
3Y
5Y
10Y
15Y
CARA
21.11.2021 - 28.11.2021

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Address: 400 Atlantic Street, Stamford, CT, United States, 06901

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.07 USD

P/E ratio

Dividend Yield

Current Year

+20 968 000 USD

Last Year

+41 867 000 USD

Current Quarter

+3 004 000 USD

Last Quarter

+4 866 000 USD

Current Year

+14 535 000 USD

Last Year

+34 601 000 USD

Current Quarter

+2 314 000 USD

Last Quarter

+3 308 000 USD

Key Figures CARA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -121 236 000 USD
Operating Margin TTM -1085.45 %
PE Ratio
Return On Assets TTM -49.3 %
PEG Ratio
Return On Equity TTM -109.8 %
Wall Street Target Price 5.07 USD
Revenue TTM 20 968 000 USD
Book Value 1.05 USD
Revenue Per Share TTM 0.39 USD
Dividend Share
Quarterly Revenue Growth YOY -7.9 %
Dividend Yield
Gross Profit TTM -56 141 000 USD
Earnings Share -2.19 USD
Diluted Eps TTM -2.19 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CARA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CARA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:2
Payout Ratio
Last Split Date 16.01.2014
Dividend Date

Stock Valuation CARA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 12.0452
Price Sales TTM 1.9917
Enterprise Value EBITDA 0.4497
Price Book MRQ 0.7316

Financials CARA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CARA

For 52 weeks

0.5 USD 4.67 USD
50 Day MA 0.8 USD
Shares Short Prior Month 2 481 772
200 Day MA 1.49 USD
Short Ratio 3.51
Shares Short 2 576 798
Short Percent 6.57 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics